Edgewise Therapeutics, Inc. (EWTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Edgewise Therapeutics, Inc. (EWTX) closed at USD 37.02 on 2026-10-14, a change of +125.5 % over the past year, with a market capitalization of USD 4.15B.

Edgewise Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Edgewise Therapeutics, Inc. key figures

Previous close

USD 37.02 (2026-10-14)

1-year change

+125.5 %

Market cap

USD 4.15B

Enterprise value

USD 3.69B

P/E ratio (trailing)

-19.49

P/E ratio (forward)

-21.03

EPS (trailing)

-1.96

EPS (forward)

-1.82

PEG ratio

n/a

Price to book

9.19

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.94

Employees

127

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Edgewise Therapeutics, Inc. and compare it with other stocks.